Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context

NCT06781450 · clinicaltrials.gov ↗

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Primary Mediastinal B Cell Lymphoma

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna